Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122719 | 0.87 | TSHR (0.39) | — | |
| SCHEMBL4110930 | 0.82 | MKNK2 (0.45) | MKNK1MKNK2 | |
| SCHEMBL4123208 | 0.80 | FGFR1 (0.48) | IRAK4 | |
| SCHEMBL4652773 | 0.77 | IRAK4 (0.43) | IRAK4MKNK1MKNK2 | |
| SCHEMBL4654969 | 0.77 | IRAK4 (0.43) | IRAK4MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL4117078 | 0.77 | IRAK4 (0.42) | IRAK4MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL4117075 | 0.77 | IRAK4 (0.42) | IRAK4MKNK1MKNK2 | |
| SCHEMBL4127174 | 0.69 | BIRC5 (0.41) | MKNK1MKNK2 | |
| SCHEMBL11956176 | 0.69 | CYP2E1 (0.33) | — | |
| SCHEMBL3771498 | 0.68 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476670-B2 | Purine derivatives, method for preparing, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2009-01-13 | — | — | US | disclosed |
| EP-1597258-B1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20070185140-A1 | Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S. A. (FR) | 2007-08-09 | — | — | US | disclosed |
| EP-1597258-A2 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073595-A2 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD THEREOF, APPLICATION OF SAME AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185140-A1 | Novel purine derivatives, method for preparing them, their application as medicinal products, pharmaceutical compositions and novel use | NR4A3, NR4A1, ADORA3 | IRAK4 1010/4885MKNK1 4657/4885MKNK2 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.